P112: ENERGIZE AND ENERGIZE-T: TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES OF MITAPIVAT IN ADULTS WITH NON--TRANSFUSION-DEPENDENT OR TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA
K Kuo,
D Layton,
H Al-Samkari,
A Kattamis,
S Sheth,
A Taher,
V Viprakasit,
C Chamberlain,
L Czapla,
S Gheuens,
M Lynch,
B Tong,
K Uhlig,
M Cappellini
Affiliations
K Kuo
1 Division of Hematology, University of Toronto, Toronto, ON, CANADA
D Layton
2 Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UNITED KINGDOM
H Al-Samkari
3 Division of Hematology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, UNITED STATES
A Kattamis
4 First Department of Pediatrics, National and Kapodistrian University of Athens BR, Athens, GREECE
S Sheth
5 Weill Cornell Medical College, New York, NY, UNITED STATES
A Taher
6 American University of Beirut, Beirut, LEBANON
V Viprakasit
7 Siriraj-Thalassemia Center, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, THAILAND
C Chamberlain
8 Agios Pharmaceuticals, Inc., Cambridge, MA, UNITED STATES
L Czapla
8 Agios Pharmaceuticals, Inc., Cambridge, MA, UNITED STATES
S Gheuens
8 Agios Pharmaceuticals, Inc., Cambridge, MA, UNITED STATES
M Lynch
8 Agios Pharmaceuticals, Inc., Cambridge, MA, UNITED STATES
B Tong
8 Agios Pharmaceuticals, Inc., Cambridge, MA, UNITED STATES
K Uhlig
8 Agios Pharmaceuticals, Inc., Cambridge, MA, UNITED STATES
